{
  "pmcid": "11529789",
  "sha256": "67764f7d3506c2a840aa1311571aae205c95a6704e5df83a5213c4671fc24fd4",
  "timestamp_utc": "2025-11-09T22:04:45.844808+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.059937768240342,
    "reading_ease": 22.17934871244637,
    "word_count": 233
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "CETUPANC Trial: A Randomised Controlled Trial Comparing Surgical Approaches in Pancreatic Ductal Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "patients with resectable pancreatic ductal adenocarcinoma (PDAC) were randomly assigned"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with resectable pancreatic ductal adenocarcinoma (PDAC) were randomly assigned to either the NT or SMA group"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to either the NT or SMA group"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to compare the no-touch (NT) approach and the superior mesenteric artery (SMA) approach"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was intraoperative CTC and cluster mobilization, measured at four time points"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was performed intraoperatively, with allocation concealed until surgery"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Patients were blinded to the intervention"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 101 patients were randomized (51 SMA, 50 NT) between January 2017 and December 2019"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Sixty-three patients with PDAC were analyzed using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Median metastasis disease-free survival (MDFS) was 12 months (IQR 6.1–not reached) in the SMA group and 18 months (IQR 12.1–not reached) in the NT group (P = 0.730)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT03340844"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}